Tissue Repair
BPC-157
BPC-157 is an experimental peptide. Learn what limited human research can tell us, FDA safety concerns, and why claimed benefits remain uncertain.
At a glance
BPC-157 is an experimental peptide. Learn what limited human research can tell us, FDA safety concerns, and why claimed benefits remain uncertain.
What is BPC-157?
BPC-157, often called Body Protection Compound 157, is discussed in experimental research and marketed for injury recovery. A marketed claim is not the same as a demonstrated clinical benefit. This guide does not recommend BPC-157 for tendon injuries, digestive conditions, or any other disease.
The available human evidence is limited. When evaluating a claim, separate laboratory or animal findings from controlled studies in people, and distinguish a small report of tolerability from proof that a treatment works.
Sources: [fda-safety] [bpc-pilot]
Human research and its limits
A 2025 pilot publication examined intravenous BPC-157 in only two adults who had already received it before the study. The investigators reported no adverse effects during a short observation period. There was no randomized comparison group, and this study did not establish effectiveness for injury healing.
Two participants cannot establish the frequency of uncommon adverse events, long-term safety, or safety in children, pregnancy, or people taking other medicines. The route and formulation studied also do not establish the safety of differently manufactured injections or oral products. The publication's reassuring conclusion must be read with these limitations in mind.
Sources: [bpc-pilot]
FDA and compounding context
BPC-157 is not an FDA-approved treatment. FDA identifies potential problems with immunogenicity, peptide-related impurities and characterization of the active ingredient, and says it lacks sufficient information to know whether BPC-157 would cause harm by the proposed routes.
Compounding policies and product approval are different questions. A nomination, advisory discussion, pharmacy offering, or label saying “research use only” does not establish that a product is approved, safe, or effective for a patient. Compounded drugs do not undergo FDA premarket review for safety, effectiveness and quality.
Sources: [fda-safety] [compounding]
Safety, interactions and dosing uncertainty
The limited evidence does not support a reliable list of expected side effects or a validated clinical dosing schedule. Absence of a reported interaction is not proof that combinations with medicines or other peptides are safe. This page therefore does not provide injection amounts, cycling instructions, or peptide-stacking protocols.
Tell a qualified healthcare professional about any product already taken, its source and formulation, other medicines, and any symptoms. Do not delay assessment of an injury or persistent digestive symptoms while trying an experimental product. Product quality concerns and uncertain biological effects are separate risks; a purity claim does not resolve either clinical effectiveness or long-term safety.
Sources: [fda-safety] [bpc-pilot]
Questions to ask about a treatment claim
Ask which controlled human study supports the exact condition, route and formulation being proposed. Ask how harms were monitored, how many people were studied, and how long follow-up lasted. Testimonials and animal experiments cannot answer those questions on their own.
Ask a clinician about established evaluation and treatment options for the underlying problem, and how any proposed experimental use differs from an approved medicine. The linked sources explain why the evidence here is not comparable to large trials of approved products.
Sources: [fda-safety] [bpc-pilot]
Frequently asked questions
These FAQs use the sources listed below. They are not independently clinically reviewed.
What is BPC-157 used for?
It is marketed and researched for uses including injury recovery, but these claims are not established clinical benefits. The small human pilot cited here did not test injury healing.
Sources: [bpc-pilot]
Is BPC-157 FDA approved?
No. FDA identifies potential safety risks and insufficient safety information. Medical supervision or a compounding claim does not turn it into an FDA-approved treatment.
Sources: [fda-safety] [compounding]
Sources and reading notes
Sources support the cited sections or FAQs, not every statement in a legacy overview. A source link is not an endorsement of a product or treatment.
[fda-safety] U.S. Food and Drug Administration — Compounding substances that may present significant safety risks
Substance-specific safety concerns; inclusion or removal from a compounding list is not marketing approval.
[bpc-pilot] Alternative Therapies in Health and Medicine / PubMed — Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (2025)
Two participants with prior exposure, short follow-up and no control group; not evidence of broad safety or effectiveness.
[compounding] U.S. Food and Drug Administration — FDA concerns with unapproved GLP-1 drugs used for weight loss
About this entry
Article updated: .
AI-assisted source synthesis prepared for Peptide Directory. No independent clinical review has been performed.